Olympia Pharmaceuticals, operating as both a 503B outsourcing facility and a 503A compounding pharmacy, has expanded its product directory to include a wide array of injectable peptides, hormones, and weight management formulations. The company markets these compounded medications—such as GLP-1 agonists and various regenerative peptides—directly to physicians and clinics for office use, bypassing standard FDA approval pathways for mass-produced drugs. This expansion reflects the growing demand for compounded alternatives to branded weight loss and longevity therapeutics.